This program is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally.

In this virtual webinar, leading expert Dr. Sue Pedersen explores personalized strategies for obesity care and the integration of treatment approaches consistent with clinical guidelines. Dr. Pedersen will review the evolution of escalation and de-escalation frameworks in clinical practice, describe the evidence-based timing for advancing therapy when lifestyle interventions are insufficient, and demonstrate how to integrate pharmacological options within structured follow-up workflows to optimize long-term patient outcomes and quality of life.

This will be followed by Consultant Endocrinologists, Dr. Mona Sharef Hashim (UAE) and Dr. Khalid Al-Madani (Saudi Arabia), who will provide a perspective from the Gulf region, focusing on the application of regional obesity guidelines in primary care, and offering practical, patient-centered communication strategies to support collaborative, bias-aware conversations, and deliver individualized obesity care in the regional context.

Accreditation: 1.5 AMA PRA Category 1 Credits™

Session Highlights

• Guidelines in practice: Initiate and sustain long-term, evidence-based obesity management plans integrating lifestyle, pharmacotherapy, and referral strategies.
• Timely reassessment: Apply international and local obesity guidelines to review progress and adjust therapy.
• Structured follow-up: Design dedicated weight-management visits with predefined monitoring metrics and escalation triggers.
• Integrated care: Embed obesity treatment within chronic disease management pathways for sustained outcomes.
• Patient-centred approach: Communicate with empathy, address bias and stigma, and co-create individualised management plans.

Who Should Watch

• Primary Care Physicians
• Primary Care Team
• Nurse Practitioners
• Physician Assistants

Presented by

Sue D. Pedersen, MD, FRCPC – Specialist in Endocrinology and Metabolism; American Board of Obesity Medicine; Clinical Professor, University of Calgary. Dr. Pedersen’s clinical research and leadership in national and global pharmacotherapy trials for obesity, as well as her authorship of the Canadian Clinical Practice Guidelines on Obesity, have shaped evidence-based strategies for diabetes and obesity management.

Mona Hashim, PhD, MSc, BSc – Assistant Professor and Clinical Training Coordinator, Department of Clinical Nutrition & Dietetics, College of Health Sciences, University of Sharjah, United Arab Emirates. A member of the Nutrition Society (UK) and licensed dietitian in both the UAE and Lebanon, Dr Hashim has played a key role in developing and accrediting nutrition programmes in higher education. Her work continues to inform evidence-based approaches to clinical nutrition and public health nutrition practice in the region.

Khalid A. Al-Madani, MPH, DSc – Consultant in Clinical Nutrition, Jeddah, Saudi Arabia. Dr Al-Madani is an accomplished public health and nutrition specialist with extensive experience in clinical nutrition, policy development, and research. Holding a Doctor of Science from Tulane University, he has led regional nutrition services for the Saudi Ministry of Health and served as a WHO advisor on multiple occasions. Dr Al-Madani is Vice President of both the Saudi Society for Environmental Sciences and the Saudi Society for Food and Nutrition, and a long-standing member of the American Dietetic Association.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Lilly.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Sue Pedersen has disclosed financial relationships within the past 24 months with the following ineligible companies: AstraZeneca, Bausch, Eli Lilly, Novo Nordisk, Janssen, Boehringer, Sanofi, Merck, Abbott, Dexcom, HLS, GSK, Bayer, Pfizer, AbbVie, Roche, Amgen, Prometic, and Regeneron. These relationships include honoraria, participation on advisory boards or speakers’ bureaus, and involvement in research and clinical trials.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Pedersen intends to discuss non-FDA uses of drug products and/or devices only in relation to products for which she has no financial relationships. She will disclose to the audience when this discussion takes place.

Dr. Mona Sharef Hashim has no financial relationships within the past 24 months with any ineligible companies to disclose. This disclosure is made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Hashim does not intend to discuss any non-FDA uses of drug products or devices.

Dr. Khalid Al-Madani has no financial relationships within the past 24 months with any ineligible companies to disclose. This disclosure is made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Al-Madani does not intend to discuss any non-FDA uses of drug products or devices.

AffinityCE staff and MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ . Physician assistants claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Participation Costs

There is no cost to participate in this program.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

This continuing education activity is active starting November 12th 2025 and will expire on November 12th 2025. Estimated time to complete this activity: 1 hour and 30 minutes.